Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T‐Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease

On November 15, 2018, the Committee for Medicinal Products for Human Use (CHMP) recommended the extension of indication for blinatumomab to include the treatment of adults with minimal residual disease (MRD) positive B‐cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab was authorized to...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Ali, Sahra, Moreau, Alexandre, Melchiorri, Daniela, Camarero, Jorge, Josephson, Filip, Olimpier, Odoardo, Bergh, Jonas, Karres, Dominik, Tzogani, Kyriaki, Gisselbrecht, Christian, Pignatti, Francesco
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2019
Teme:
Regulatory Issues: EMA
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7160312/
https://ncbi.nlm.nih.gov/pubmed/32297447
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0559
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items